Longboard Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Longboard Pharmaceuticals's earnings have been declining at an average annual rate of -35.4%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually.
Key information
-35.4%
Earnings growth rate
15.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -133.0% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely
Mar 16Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?
Oct 03
We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate
Dec 25Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth
Sep 10We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely
May 28Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans
Feb 11Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation
Oct 27Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business
Jun 12Longboard Pharmaceuticals EPS beats by $0.29
May 10Revenue & Expenses BreakdownBeta
How Longboard Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -54 | 13 | 44 |
| 30 Sep 23 | 0 | -51 | 12 | 41 |
| 30 Jun 23 | 0 | -49 | 12 | 40 |
| 31 Mar 23 | 0 | -46 | 11 | 36 |
| 31 Dec 22 | 0 | -44 | 10 | 35 |
| 30 Sep 22 | 0 | -41 | 10 | 32 |
| 30 Jun 22 | 0 | -36 | 10 | 27 |
| 31 Mar 22 | 0 | -32 | 9 | 22 |
| 31 Dec 21 | 0 | -28 | 8 | 20 |
| 30 Sep 21 | 0 | -29 | 6 | 16 |
| 30 Jun 21 | 0 | -25 | 5 | 13 |
| 31 Mar 21 | 0 | -20 | 4 | 9 |
Quality Earnings: LBPH is currently unprofitable.
Growing Profit Margin: LBPH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LBPH's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LBPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LBPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-14.6%).
Return on Equity
High ROE: LBPH has a negative Return on Equity (-132.99%), as it is currently unprofitable.